PLUR Key Statistics, Chart & Performance
The current stock price of PLUR is 3.3 USD. In the past month the price increased by 6.11%. In the past year, price decreased by -26.34%.
PLUR Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PLUR. When comparing the yearly performance of all stocks, PLUR is a bad performer in the overall market: 85.98% of all stocks are doing better.
PLUR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PLUR. PLUR has a bad profitability rating. Also its financial health evaluation is rather negative.
PLUR Financial Highlights
Over the last trailing twelve months PLUR reported a non-GAAP Earnings per Share(EPS) of -3.1. The EPS increased by 24.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -66.97% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PLUR Forecast & Estimates
7 analysts have analysed PLUR and the average price target is 12.24 USD. This implies a price increase of 270.91% is expected in the next year compared to the current price of 3.3.
For the next year, analysts expect an EPS growth of 12.2% and a revenue growth 63.28% for PLUR
PLUR Ownership
About PLUR
Company Profile
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. The firm is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The firm has a portfolio of over 140 granted patents in approximately 52 countries.
Company Info
PLURI INC
Matam Advanced Technology Park, Building No. 5
Haifa IL
Employees: 106
Phone: 972747107171
PLURI INC / PLUR FAQ
What does PLURI INC do?
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. The firm is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The firm has a portfolio of over 140 granted patents in approximately 52 countries.
Can you provide the latest stock price for PLURI INC?
The current stock price of PLUR is 3.3 USD. The price decreased by -4.1% in the last trading session.
Does PLUR stock pay dividends?
PLUR does not pay a dividend.
What is the ChartMill rating of PLURI INC stock?
PLUR has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is PLURI INC (PLUR) stock traded?
PLUR stock is listed on the Nasdaq exchange.
What sector and industry does PLURI INC belong to?
PLURI INC (PLUR) operates in the Health Care sector and the Biotechnology industry.
Can you provide the number of employees for PLURI INC?
PLURI INC (PLUR) currently has 106 employees.